Monthly
US$200
Billed every month
Sign in to subscribeMetoprolol Succinate Extended-release Capsules
Matched- Active ingredients (original)
- METOPROLOL SUCCINATE
- Dosage form (original)
- CAPSULE, EXTENDED RELEASE
- Route (original)
- ORAL
Read these limits
- US patent expiration does not establish Chinese patent expiration. Dates here come from the US Orange Book; Chinese patent status needs separate checking.
- The Orange Book lists holder-submitted patents and does not cover all related patents.
- “Unmatched” means no English ingredient-name counterpart in the Chinese official-name sources loaded here; it does not mean no Chinese approval or filing. A zero count means a Chinese name is matched but no records were found in the loaded source. Source dates appear below.
- This page contains no sales or market-size data and cannot establish development value.
- Names on unmatched rows are the original FDA Orange Book names, without Chinese translation. The same ingredient may have a different generic name in China.
US-approved products
Application numbers, product numbers and original fields are retained. Marketing status is shown as listed in the source.
Earliest approval2018/01/26
ANDA applications0
RLD applicantSUN PHARMA INDUSTRIES LTD
Currently marketed products: 4 · Counts FDA prescription and OTC marketing categories as listed; discontinued or unknown categories are excluded.
| Application / product number | Brand name (original) | Applicant (original) | Dosage form (original) | Route (original) | Strength (original) | Earliest approval | RLD / RS | Marketing status (original) | Official source |
|---|---|---|---|---|---|---|---|---|---|
| N210428-001 | KAPSPARGO SPRINKLE | SUN PHARMA INDUSTRIES LTD | CAPSULE, EXTENDED RELEASE | ORAL | METOPROLOL SUCCINATE: EQ 25MG TARTRATE | 2018/01/26 | Y / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N210428-002 | KAPSPARGO SPRINKLE | SUN PHARMA INDUSTRIES LTD | CAPSULE, EXTENDED RELEASE | ORAL | METOPROLOL SUCCINATE: EQ 50MG TARTRATE | 2018/01/26 | Y / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N210428-003 | KAPSPARGO SPRINKLE | SUN PHARMA INDUSTRIES LTD | CAPSULE, EXTENDED RELEASE | ORAL | METOPROLOL SUCCINATE: EQ 100MG TARTRATE | 2018/01/26 | Y / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N210428-004 | KAPSPARGO SPRINKLE | SUN PHARMA INDUSTRIES LTD | CAPSULE, EXTENDED RELEASE | ORAL | METOPROLOL SUCCINATE: EQ 200MG TARTRATE | 2018/01/26 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
Listed US patents
*PED rows, substance/product flags, use codes and delisting-request flags are retained without determining legal effect.
Latest listed patent expiration2035/07/09
Substance patent expiration (DS flag)—
This column includes only source rows explicitly flagged DS. A PED row without that flag is not assigned one by this site.
| Application / product number | Patent number | Listed expiration | Substance / product flags | Use code | Delisting request | Official source |
|---|---|---|---|---|---|---|
| N210428-001 | 9504655 | 2035/07/09 | — / Y | — | — | openFDA ↗ |
| N210428-001 | 9700530 | 2035/07/09 | — / Y | — | — | openFDA ↗ |
| N210428-002 | 9504655 | 2035/07/09 | — / Y | — | — | openFDA ↗ |
| N210428-002 | 9700530 | 2035/07/09 | — / Y | — | — | openFDA ↗ |
| N210428-003 | 9504655 | 2035/07/09 | — / Y | — | — | openFDA ↗ |
| N210428-003 | 9700530 | 2035/07/09 | — / Y | — | — | openFDA ↗ |
| N210428-004 | 9504655 | 2035/07/09 | — / Y | — | — | openFDA ↗ |
| N210428-004 | 9700530 | 2035/07/09 | — / Y | — | — | openFDA ↗ |
Exclusivity source records
FDA exclusivity code list ↗Latest exclusivity expiration: —
| Application / product number | Exclusivity code | Listed expiration | Official source |
|---|---|---|---|
| Not listed | |||
Chinese record details
Chinese product landscape ↗The four-zero filter applies only to matched rows: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. Unmatched rows have no Chinese counts. Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Catalog holders 6
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Shanghai Hui Yong Pharmaceutical Co., Ltd. romanized | 国药准字H2026385647.5mg | 2026/04/07 | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025626995mg | 2025/12/16 | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025627023.75mg | 2025/12/16 | Official source ↗ |
| Hangzhou Mu Yuan Biopharmaceuticals Technology Co., Ltd. romanized | 国药准字H2025618247.5mg | 2025/12/09 | Official source ↗ |
| Fujian Sheng Bao Nuo Pharmaceuticals Research and Development Co., Ltd. romanized | 国药准字H2024909647.5mg | 2024/10/16 | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | 2024/06/28 | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024419995mg | 2024/06/28 | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024419823.75mg | 2024/06/28 | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20243717See source | 2024/05/15 | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20243716See source | 2024/05/15 | Official source ↗ |
NHSA approval numbers 10
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024419995mg | — | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025627023.75mg | — | Official source ↗ |
| Fujian Sheng Bao Nuo Pharmaceuticals Research and Development Co., Ltd. romanized | 国药准字H2024909647.5mg | — | Official source ↗ |
| Hangzhou Mu Yuan Biopharmaceuticals Technology Co., Ltd. romanized | 国药准字H2025618247.5mg | — | Official source ↗ |
| Shanghai Hui Yong Pharmaceutical Co., Ltd. romanized | 国药准字H2026385647.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025627023.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025627023.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371623.75mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024419823.75mg | — | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025626995mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025626995mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025626995mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | 国药准字H2025626995mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H2024371747.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H2024420047.5mg | — | Official source ↗ |
Under review 4
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Jilin Tian Heng Ying Rui Pharmaceutical Co., Ltd. romanized | CYHS2602343 | 2026/09/20 | Official source ↗ |
| Jilin Tian Heng Ying Rui Pharmaceutical Co., Ltd. romanized | CYHS2602342 | 2026/09/20 | Official source ↗ |
| Shandong Hua Su Pharmaceutical Co., Ltd. romanized | CYHS2601415 | 2026/06/15 | Official source ↗ |
| Shandong Hua Su Pharmaceutical Co., Ltd. romanized | CYHS2601414 | 2026/06/15 | Official source ↗ |
Generic-filing companies this year 2
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Jilin Tian Heng Ying Rui Pharmaceutical Co., Ltd. romanized | CYHS2602343 | 2026/09/20 | Official source ↗ |
| Jilin Tian Heng Ying Rui Pharmaceutical Co., Ltd. romanized | CYHS2602342 | 2026/09/20 | Official source ↗ |
| Shandong Hua Su Pharmaceutical Co., Ltd. romanized | CYHS2601415 | 2026/06/15 | Official source ↗ |
| Shandong Hua Su Pharmaceutical Co., Ltd. romanized | CYHS2601414 | 2026/06/15 | Official source ↗ |
API companies with A status 19
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Ipca Laboratories Limited | Y20230001162 | 2026/04/03 | Official source ↗ |
| Bai Yun Shandong Tai Shang Qiu Pharma Co., Ltd. romanized | Y20240000368 | 2025/12/09 | Official source ↗ |
| Shandong Hua Su Pharmaceutical Co., Ltd. romanized | Y20240000199 | 2026/09/21 | Official source ↗ |
| ATUL BIOSCIENCE LTD. | Y20230000090 | 2024/11/26 | Official source ↗ |
| Gui Lin Hua Xin Pharmaceutical Co., Ltd. romanized | Y20230000348 | 2026/03/12 | Official source ↗ |
| Ipca Laboratories Limited | Y20220000474 | 2024/08/07 | Official source ↗ |
| Dr.Reddy's Laboratories Ltd. | Y20220000109 | 2024/01/16 | Official source ↗ |
| Shandong Qidu Pharmaceutical Co., Ltd. | Y20210000268 | 2026/08/25 | Official source ↗ |
| CTX Lifesciences Pvt. Ltd. | Y20190021559 | 2026/09/17 | Official source ↗ |
| ZHE JIANG HUA HAI PHARMACEUTICALCO.,LTD. | Y20200001420 | 2023/07/06 | Official source ↗ |
| Shandong Xin Shi Dai Pharma Co., Ltd. romanized | Y20200000203 | 2026/04/27 | Official source ↗ |
| AstraZeneca AB | Y20190009941 | — | Official source ↗ |
| AstraZeneca AB | Y20190009940 | — | Official source ↗ |
| Zhejiang Pu Luo Jia Yuan Pharma Co., Ltd. romanized | Y20190009774 | 2025/11/25 | Official source ↗ |
| Guangzhou Bai Yun Shan Han Fang Xian Dai Pharma Co., Ltd. romanized | Y20190007575 | 2026/06/17 | Official source ↗ |
| Shanghai Xin Yi Bai Lu Da Pharma Co., Ltd. romanized | Y20190006716 | 2023/03/24 | Official source ↗ |
| Changzhou Si Yao Pharmaceutical Co., Ltd. romanized | Y20190004561 | 2026/03/18 | Official source ↗ |
| Zhejiang Pu Luo Jia Yuan Pharma Co., Ltd. romanized | Y20190000080 | 2026/04/08 | Official source ↗ |
| Zhejiang Hai Xiang Chuan Nan Pharma Co., Ltd. romanized | Y20180001385 | 2026/10/28 | Official source ↗ |
| AstraZeneca AB | Y20170001948 | 2024/09/24 | Official source ↗ |
| AstraZeneca AB | Y20170001947 | 2024/09/24 | Official source ↗ |
| Sun Pharmaceutical Industries Limited | Y20170001466 | 2024/11/07 | Official source ↗ |
| MOEHS IBERICA S.L. | Y20170001403 | 2026/10/16 | Official source ↗ |
| CTX Lifesciences Pvt. Ltd. | Y20170000853 | 2026/01/02 | Official source ↗ |
| Yi Chang Dong Yang Guang Chang Jiang Pharma Co., Ltd. romanized | Y20170000556 | 2026/07/14 | Official source ↗ |
Trial registrations 2025/2026 —
Not loaded
Sources and dates
- FDA Orange Book
- 2026/11/06
- CDE acceptance and review
- 2026/11/13 06:42
- Chemical Drug Catalog
- 2026/11/13 06:39
- API registration records
- 2026/11/13 06:41
- NHSA drug code database
- 2026/10/23
- Trial registry
- 2026/11/13 08:09 · Incomplete coverage
Chinese counts use complete ingredient, dosage-form and route matches. Unmatched and partial rows show name-source matching only and make no finding about Chinese approvals or filings. Trials cover registration-number years 2025/2026 only.
Comparison generated: 2026/11/13 18:41 · openFDA Orange Book ↗
Name and dosage-form matching sources
- NMPA reference-product directory, Shaanxi MPA republication ↗ · 29-55 · 2020/08/06
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy